Related Experiment Video
Updated: Aug 20, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Pharmacogenomics in cancer therapy: is host genome variability important?
William P Petros1, William E Evans
1Mary Babb Randolph Cancer Center and West Virginia University School of Pharmacy, WV 26506, USA. wpetros@hsc.wvu.edu
Abstract:
Pharmacogenomics aims to elucidate the genomic determinants of drug disposition and effect. Because cancer chemotherapy is relatively nonspecific and has narrow therapeutic indices, there is great potential for pharmacogenomics to improve treatment outcomes by either reducing toxicity or increasing efficacy. The diversity of therapeutic targets for anticancer drugs and the intensity of clinical pharmacology research in oncology have provided many examples of clinically relevant pharmacogenomic applications. Important elements that are discussed in this article include the association of genetic variability in the metabolism, intracellular transport and targets of anticancer drugs. In addition, we summarize where the field stands currently, and how information from the host and tumor might be integrated into decision making.
Insights
Pharmacogenomics uses genetic information to tailor cancer chemotherapy, aiming to reduce toxicity and improve treatment effectiveness. This approach considers individual genetic variations impacting drug response for better patient outcomes.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Cancer chemotherapy often lacks specificity and has narrow therapeutic indices.
- Significant potential exists to enhance treatment outcomes by reducing toxicity or increasing efficacy.
- Pharmacogenomics offers a promising avenue for optimizing cancer drug therapy.
Purpose of the Study:
- To explore the role of pharmacogenomics in cancer treatment.
- To discuss the impact of genetic variability on anticancer drug disposition and effect.
- To summarize the current state and future integration of pharmacogenomic data in oncology.
Main Methods:
- Review of existing literature on pharmacogenomics in oncology.
- Analysis of genetic variability in drug metabolism, transport, and targets.
- Discussion of integrating host and tumor genetic information.
Main Results:
- Genetic variability significantly influences anticancer drug metabolism, intracellular transport, and drug targets.
- Numerous clinically relevant pharmacogenomic applications have been identified in oncology.
- The field is advancing towards integrating diverse genetic data for clinical decision-making.
Conclusions:
- Pharmacogenomics holds significant promise for personalizing cancer chemotherapy.
- Understanding individual genetic profiles can lead to improved drug efficacy and reduced toxicity.
- Future directions involve integrating host and tumor genomics for optimized cancer treatment strategies.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
